Ekf Diagnostics Holding PLC (EKF) Given Corporate Rating at N+1 Singer
A number of other research firms have also issued reports on EKF. Panmure Gordon restated a buy rating and issued a GBX 14 ($0.18) target price on shares of Ekf Diagnostics Holding PLC in a report on Wednesday, July 6th. FinnCap restated an under review rating on shares of Ekf Diagnostics Holding PLC in a report on Tuesday, August 30th.
Shares of Ekf Diagnostics Holding PLC (LON:EKF) traded up 1.20% on Friday, hitting GBX 17.33. The company’s stock had a trading volume of 446,529 shares. The stock’s market capitalization is GBX 74.31 million. The stock’s 50 day moving average price is GBX 14.95 and its 200 day moving average price is GBX 13.25. Ekf Diagnostics Holding PLC has a 52 week low of GBX 7.00 and a 52 week high of GBX 23.45.
In other news, insider Mills,Christopher H. B acquired 9,000,000 shares of the business’s stock in a transaction that occurred on Friday, July 15th. The stock was acquired at an average cost of GBX 15 ($0.20) per share, for a total transaction of £1,350,000 ($1,762,172.04).
Ekf Diagnostics Holding PLC Company Profile
EKF Diagnostics Holdings Plc is focused on the In-Vitro Diagnostic device (IVD) market place. The Company is engaged in the designing, development, manufacture and selling of diagnostic instruments, reagents and certain ancillary products. This activity takes place across various geographical locations which include the United States America, Germany, Poland, Russia, United Kingdom and Ireland.
Receive News & Stock Ratings for Ekf Diagnostics Holding PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ekf Diagnostics Holding PLC and related stocks with our FREE daily email newsletter.